Crystalline solids of 3-palmitoyl-amide-1,2-propanediol and 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane, and methods for preparing and using them.

Abstract

To provide crystalline solids of 3-palmitoyl-amido-1,2-propanediol.SOLUTION: Aspects of the disclosure include crystalline solids of 3-palmitoyl-amido-1,2-propanediol and 3-palmitoyl-amido-2-hydroxy-1-dimethoxytriphenylmethylether-propane. Methods for preparing the crystalline solids of 3-palmitoyl-amido-1,2-propanediol and single crystals of 3-palmitoyl-amido-2-hydroxy-1-dimethoxytriphenylmethylether-propane are also provided. Methods for preparing 3-palmitoyl-amido-2-hydroxy-1-dimethoxytriphenylmethylether-propane from a crystalline solid of 3-palmitoyl-amido-1,2-propanediol are also described.SELECTED DRAWING: None

Description

[Technical Field]

[0001] Cross-reference of related applications This application claims priority to U.S. Provisional Patent Application No. 62 / 926,810, filed October 28, 2019, the disclosure of which is incorporated herein by reference.

[0002] Introduction Imeterstat is a telomerase inhibitor that binds with high affinity to the template region of the RNA component of telomerase. Studies have shown that imeterstat inhibits telomerase activity and is effective against cell proliferation in many different cancer cell lines and human tumors. Imeterstat is used in clinical trials in patients with hematological malignancies. Clinical trials in patients with myelofibrosis have shown that imeterstat can achieve complete clinical remission in certain patients. In these patients, imeterstat resulted in antagonism of myelofibrosis and morphological and molecular remission.

[0003] The structure of imetellstat contains an N3'→P5' thiophosphoamidate oligonucleotide. The synthesis of imetellstat is carried out by solid-phase oligonucleotide synthesis, in which a first phosphoramidite nucleotide is bound to a support and subsequently sulfurized. Chain extension of the oligonucleotide component is achieved by repeated reactions of the 3'-amino group of the solid-phase support-bound oligonucleotide with additional nucleotide phosphoramidite monomers. The oligonucleotide of imetellstat is bound to the solid-phase support via a palmitoyl-amide linker. Therefore, this fatty acid-amide linker is a component in the synthesis of imetellstat. [Overview of the project] [Means for solving the problem]

[0004] The embodiments of the disclosure include crystalline solids of 3-palmitoyl-amide-1,2-propanediol (formula I): [ka]

[0005] In some embodiments, the crystalline solid of 3-palmitoyl-amide-1,2-propanediol has an X-ray powder diffraction (XRPD) pattern containing a peak at approximately 8.25°2θ. In certain embodiments, the crystalline solid of 3-palmitoyl-amide-1,2-propanediol has an X-ray powder diffraction (XRPD) pattern containing one or more peaks at approximately 2.75°2θ, approximately 6°2θ, approximately 3.8°2θ, approximately 15°2θ, approximately 26.3°2θ, approximately 30.5°2θ, and approximately 33.1°2θ. The crystalline solid of 3-palmitoyl-amide-1,2-propanediol is characterized in some cases by a single weight loss step by thermogravimetric analysis (TGA). In certain cases, the weight loss step begins at approximately 200.5°C. In some embodiments, the crystalline solid of 3-palmitoyl-amide-1,2-propanediol exhibits a first endothermic reaction at approximately 79.3°C and a second endothermic reaction at approximately 102.5°C, as determined by differential scanning calorimetry (DSC). In these embodiments, the second endothermic reaction is a single peak endothermic reaction.

[0006] Methods for preparing a crystalline solid of 3-palmitoyl-amide-1,2-propanediol are also provided. In a particular embodiment, 3-palmitoyl-amide-1,2-propanediol is contacted with one or more solvents to produce a 3-palmitoyl-amide-1,2-propanediol composition, which is then precipitated to produce a crystalline solid of 3-palmitoyl-amide-1,2-propanediol. In some embodiments, 3-palmitoyl-amide-1,2-propanediol is contacted with a polar solvent. In other embodiments, 3-palmitoyl-amide-1,2-propanediol is contacted with a nonpolar solvent. In yet another embodiment, 3-palmitoyl-amide-1,2-propanediol is contacted with a mixture of a polar solvent and a nonpolar solvent. The solvent may further contain an organic base such as triethylamine. In some embodiments, the solvent is selected from tetrahydrofuran, methyltetrahydrofuran, dichloromethane, isopropyl acetate, ethyl acetate, 1,2-dichloroethane (DCE), dimethylformamide (DMF), acetone, dimethylacetamide, dimethyl sulfoxide (DMSO), acetonitrile, toluene, 2-methylbutan-2-ol (tAmOH), and N-methyl-2-pyrrolidone (NMP), or a combination thereof. In some cases, the solvent is selected from tetrahydrofuran, methyltetrahydrofuran, and dichloromethane. In a particular case, the solvent is tetrahydrofuran. In certain embodiments, precipitation of a crystalline solid of 3-palmitoyl-amide-1,2-propanediol includes heating a 3-palmitoyl-amide-1,2-propanediol composition to produce a heated composition (e.g., solubilizing 3-palmitoyl-amide-1,2-propanediol in a solvent) and cooling the heated 3-palmitoyl-amide-1,2-propanediol composition to produce a crystalline solid of 3-palmitoyl-amide-1,2-propanediol.

[0007] A method for preparing 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane from 3-palmitoyl-amide-1,2-propanediol is also described. In the implementation of the method of the subject according to a particular embodiment, a solvent is contacted with a crystalline solid of 3-palmitoyl-amide-1,2-propanediol to produce a precursor composition, and the precursor composition is contacted with a composition containing dimethoxytriphenylmethyl chloride to produce a composition having 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane. In some embodiments, the solvent is tetrahydrofuran, methyltetrahydrofuran, dichloromethane, isopropyl acetate (iPrOAc), ethyl acetate, 1,2-dichloroethane (DCE), dimethylformamide (DMF), acetone, dimethyl sulfoxide (DMSO), acetonitrile, toluene, 2-methylbutan-2-ol (tAmOH), N-methyl-2-pyrrolidone (NMP), or a combination thereof. In some cases, the solvent is selected from tetrahydrofuran, methyltetrahydrofuran, dichloromethane, isopropyl acetate, acetonitrile, toluene, 2-methylbutan-2-ol (tAmOH), and N-methyl-2-pyrrolidone (NMP). In certain specific cases, the solvent is selected from methyltetrahydrofuran, tetrahydrofuran, and dichloromethane.

[0008] In some embodiments, the precursor composition includes a base, such as an organic base. For example, the base may be 1,8-bis(dimethylamino)naphthalene (proton sponge), imidazole, 1,8-diazabicyclo[5.4.0]undeca-7-ene (DBU), 2,4,6-trimethylpyridine (collidine), triethylamine (TEA), potassium carbonate, sodium methoxide, tetramethylethylenediamine (TMEDA), or dimethylaminoethanol. In some cases, the base is selected from 1,8-bis(dimethylamino)naphthalene (proton sponge), tetramethylethylenediamine (TMEDA), and triethylamine (TEA). In a particular case, the base is triethylamine.

[0009] In other embodiments, the precursor composition includes additives. For example, the additive may be calcium oxide, magnesium oxide, boric acid, tetra-n-butylammonium fluoride (TBAF), 4-dimethylaminopyridine (DMAP), copper chloride (CuCl2), ytterbium(III) chloride (YbCl3), or 1,4-diazabicyclo[2.2.2]octane (DABCO). In some cases, the additive is selected from tetra-n-butylammonium fluoride (TBAF), magnesium oxide, and boric acid. In certain specific cases, the additive is magnesium oxide.

[0010] In certain cases, the crystalline solid of 3-palmitoyl-amide-1,2-propanediol has an X-ray powder diffraction (XRPD) pattern containing one or more peaks at approximately 2.75°2θ, 6°2θ, 3.8°2θ, 8.25°2θ, 15°2θ, 26.3°2θ, 30.5°2θ, and 33.1°2θ. In some cases, the crystalline solid of 3-palmitoyl-amide-1,2-propanediol is characterized by a single weight loss step by thermogravimetric analysis (TGA). In certain cases, the weight loss step begins at approximately 200.5°C. In some embodiments, the crystalline solid of 3-palmitoyl-amide-1,2-propanediol exhibits a first endothermic reaction at approximately 79.3°C and a second endothermic reaction at approximately 102.5°C by differential scanning calorimetry (DSC).

[0011] In some cases, the method further comprises forming one or more single crystals of 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane (e.g., by recrystallization). In these embodiments, 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane is brought into contact with a solvent to precipitate a crystalline solid of 3-palmitoyl-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane from the solvent. In some cases, the solvent is a polar solvent. In other cases, the solvent is a nonpolar solvent. In yet another case, the solvent is a mixture of a polar solvent and a nonpolar solvent. In certain embodiments, forming a crystalline solid of 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane involves heating a 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane composition to produce a heated composition, and then cooling the heated composition to produce a crystalline solid of 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane, such as one or more single crystals of 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane.

[0012] The aspects of the disclosure also include crystalline solids of 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane (formula II). [ka]

[0013] In certain cases, the crystalline solid of 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane is a single crystal of 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane. The crystalline solid according to the embodiment is in monoclinic form. Each unit cell in the crystalline solid contains two different conformations of 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane, such as the bent conformation and the linear conformation. In the embodiment, each conformation of 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane (bent and linear) is present in the unit cell in a 1:1 ratio. Each unit cell in the crystalline solid contains four molecules of 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane. In some embodiments, the unit cell has dimensions of approximately 8.44 Å × approximately 26.56 Å × approximately 10.06 Å, and the volume of the unit cell is approximately 2254.8 Å. 3 The subject, 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenyl ether-propane crystalline solid, has a concentration of approximately 1.2 g / cm³. 3 ~Approx. 1.3g / cm 3 It has a density and a polymorphic purity of 95% or more.

[0014] Methods for preparing crystalline solids of 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane are also provided. In a particular embodiment, 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane is contacted with one or more solvents to produce a 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane composition, which is then precipitated to produce crystalline solids of 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane, such as one or more single crystals of 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane. In some embodiments, 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane is contacted with a polar solvent. In other embodiments, 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane is contacted with a non-polar solvent. In other embodiments, 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane is brought into contact with a mixture of a polar solvent and a nonpolar solvent. In certain cases, the polar solvent is dichloromethane and the nonpolar solvent is pentane. In certain embodiments, precipitation of a crystalline solid of 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane includes heating the 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane composition to produce a heated composition (e.g., solubilizing 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane in a solvent) and cooling the heated 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane composition to produce a crystalline solid of 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane. [Brief explanation of the drawing]

[0015] [Figure 1] This shows a comparison of the X-ray powder diffraction patterns of polymorphic crystalline solids of 3-palmitoyl-amide-1,2-propanediol formed from solutions of (b) THF, (c) 2-methyl THF, and (d) DCM with (a) 3-palmitoyl-amide-1,2-propanediol starting materials. [Figure 2] The graph in Figure 2 shows a thermogram from thermogravimetric analysis (TGA) of a polymorphic crystalline solid of 3-palmitoyl-amide-1,2-propanediol formed from a solution of THF according to a particular embodiment. The graph in Figure 2 also shows a differential scanning calorimetry (DSC) plot of a polymorphic crystalline solid of 3-palmitoyl-amide-1,2-propanediol formed from THF according to a particular embodiment. [Figure 3] This shows a comparison of the DSC plot of the polymorphic crystalline solid of 3-palmitoyl-amide-1,2-propanediol formed from THF with the DSC plot of the 3-palmitoyl-amide-1,2-propanediol starting material. [Figure 4A] The Oak Ridge Thermal Vibrational Ellipsoid (ORTEP) plots for two different conformations of 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane, determined by X-ray crystallography, are shown. [Figure 4B] It shows a unit cell of crystalline 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane. [Figure 4C] A diagram of the crystal packing of 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane along the first axis is shown. [Figure 4D] This shows crystal packing of 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane along the second axis. [Figure 4E] This shows the intermolecular hydrogen bonding between conformer A and conformer B along the second crystal structure analysis axis. [Modes for carrying out the invention]

[0016] Select the definition of the chemical term. The following terms have the meanings set forth below unless otherwise indicated. Any undefined terms have the meanings recognized in the art.

[0017] As used herein, the terms “phosphate” and “phosphate group” include thiophosphate groups and oxophosphate groups.

[0018] As used herein, the term "phosphoramidite amino group" refers to an amino group bonded to the phosphorus atom of a phosphoramidite group --NR 4 R 5 The term "phosphoramidite nitrogen" refers to the nitrogen atom of the phosphoramidite amino group.

[0019] "Alkyl" refers to a monovalent saturated aliphatic hydrocarbyl group having 1 to 10 carbon atoms, such as 1 to 6 carbon atoms (e.g., "1 to 6 carbon atom alkyl"), 1 to 5 carbon atoms (e.g., "1 to 5 carbon atom alkyl"), 1 to 4 carbon atoms (e.g., "1 to 4 carbon atom alkyl"), or 1 to 3 carbon atoms (e.g., "1 to 3 carbon atom alkyl"). Examples of this term include linear and branched hydrocarbyl groups such as methyl (CH3-), ethyl (CH3CH2-), n-propyl (CH3CH2CH2-), isopropyl ((CH3)2CH-), n-butyl (CH3CH2CH2CH2-), isobutyl ((CH3)2CHCH2-), sec-butyl ((CH3)(CH3CH2)CH-), t-butyl ((CH3)3C-), n-pentyl (CH3CH2CH2CH2CH2-), and neopentyl ((CH3)3CCH2-).

[0020] The term "substituted alkyl" refers to a group in which one or more carbon atoms in an alkyl chain are optionally -O-, -N-, -S-, or -S(O) n-(where n is 0 to 2), -NR- (where R is hydrogen or alkyl), etc., are replaced by heteroatoms, and alkoxy, substituted alkoxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, acyl, acylamino, acyloxy, amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azide, cyano, halogen, hydroxyl, oxo, thioketone, carboxyl, carboxyalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substituted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-aryl, -SO-heteroaryl, -SO2-alkyl, -SO2-aryl, -SO2-heteroaryl, and -NR a R b (R a and R b may be the same or different and are selected from the group consisting of hydrogen, optionally substituted alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl, and heterocyclic), and refers to an alkyl group as defined herein having 1 to 5 substituents selected from the group. In some cases, "substituted alkyl" is alkoxy, cycloalkyl, cycloalkenyl, acyl, acylamino, acyloxy, amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azide, cyano, halogen, hydroxyl, carboxyl, carboxyalkyl, thiol, thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclooxy, sulfonamide, and -NR a R b (R a and R b may be the same or different and are selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl, and heterocyclic), and refers to an alkyl group as defined herein having 1 to 5 substituents selected from the group.

[0021] "Alkylene" is either a linear or branched chain, preferably having 1 to 6 carbon atoms, more preferably 1 to 3 carbon atoms, and optionally -O-, -NR 10 -, -NR 10 C(O)-, -C(O)NR 10 This term refers to a divalent aliphatic hydrocarbyl group that is interrupted by one or more groups selected from the following. Examples of this term include methylene (-CH2-), ethylene (-CH2CH2-), n-propylene (-CH2CH2CH2-), isopropylene (-CH2CH(CH3)-), (-C(CH3)2CH2CH2-), (-C(CH3)2CH2C(O)-), (-C(CH3)2CH2C(O)NH-), and (-CH(CH3)CH2-).

[0022] "Substitutive alkylene" refers to an alkylene group having 1 to 3 hydrogen atoms replaced by substituents, as described in the definition of "substitution" below for carbon.

[0023] The term "alkane" refers to alkyl and alkylene groups as defined herein.

[0024] The terms "alkylaminoalkyl," "alkylaminoalkenyl," and "alkylaminoalkynyl" are R ’ However, R is an alkyl group as defined herein. ” However, R is an alkylene, alkenylene, or alkynylene group as defined herein. ’ NHR ” - Refers to the base.

[0025] The terms "alkalyl" or "aralkyl" refer to alkylene, substituted alkylene, and aryl, as defined herein, to the -alkylene-aryl and -substituted alkylene-aryl groups.

[0026] "Alkoxy" refers to an -O-alkyl group, where alkyl is as defined herein. Examples of alkoxys include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, t-butoxy, sec-butoxy, and n-pentoxy. The term "alkoxy" also refers to alkenyl-O-, cycloalkyl-O-, cycloalkenyl-O-, and alkynyl-O- groups, where alkenyl, cycloalkyl, cycloalkenyl, and alkynyl are as defined herein.

[0027] The term "substituted alkoxy" refers to the substituted alkyl-O-, substituted alkenyl-O-, substituted cycloalkyl-O-, substituted cycloalkenyl-O-, and substituted alkynyl-O- groups, as defined herein.

[0028] The term "alkoxyamino" refers to an alkoxy group as defined herein, where alkoxy is an -NH-alkoxy group.

[0029] The term "haloalkoxy" refers to an alkyl-O- group in which one or more hydrogen atoms on the alkyl group are substituted with a halo group, such as trifluoromethoxy.

[0030] The term "haloalkyl" refers to the substituted alkyl groups described above, in which one or more hydrogen atoms on the alkyl group are replaced by a halo group. Examples of such groups include, but are not limited to, fluoroalkyl groups such as trifluoromethyl, difluoromethyl, and trifluoroethyl.

[0031] The term "alkylalkoxy" refers to alkyl, substituted alkyl, alkylene, and substituted alkyl groups, as defined herein, including alkyl-O-alkyl, alkylene-O-substituted alkyl, substituted alkylene-O-alkyl, and substituted alkylene-O-substituted alkyl groups.

[0032] The term "alkylthioalkoxy" refers to alkyl, substituted alkyl, alkylene, and substituted alkyl groups, as defined herein, including alkyl-S-alkyl, alkylene-S-substituted alkyl, substituted alkylene-S-alkyl, and substituted alkylene-S-substituted alkyl groups.

[0033] "Alkenyl" refers to a linear or branched hydrocarbyl group having 2 to 6 carbon atoms, preferably 2 to 4 carbon atoms, and at least 1, preferably 1 to 2 double bond unsaturated sites. Examples of this term include be-vinyl, allyl, and buta-3-en-1-yl. This term includes cis and trans isomers, or mixtures of these isomers.

[0034] The term "substituted alkenyl" refers to an alkenyl group as defined herein having one to five substituents or one to three substituents, selected from alkoxy, substituted alkoxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azide, cyano, halogen, hydroxyl, oxo, thioketo, carboxyl, carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substituted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-substituted alkyl, -SO-aryl, -SO-heteroaryl, -SO2-alkyl, -SO2-substituted alkyl, -SO2-aryl, and -SO2-heteroaryl.

[0035] "Alkynyl" refers to a monovalent linear or branched hydrocarbyl group having 2 to 6 carbon atoms, preferably 2 to 3 carbon atoms, and at least 1, preferably 1 to 2 triple-bond unsaturated sites. Examples of such alkynyl groups include acetylenyl (-C≡CH) and propargyl (-CH2C≡CH).

[0036] The term "substituted alkynyl" refers to an alkynyl group as defined herein, having one to five substituents or one to three substituents, selected from alkoxy, substituted alkoxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azide, cyano, halogen, hydroxyl, oxo, thioketo, carboxyl, carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substituted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-substituted alkyl, -SO-aryl, -SO-heteroaryl, -SO2-alkyl, -SO2-substituted alkyl, -SO2-aryl, and -SO2-heteroaryl.

[0037] "Alkynyloxy" refers to an -O-alkynyl group, where alkynyl is defined herein. Examples of alkynyloxy include ethynyloxy and propynyloxy.

[0038] "Acyl" refers to the groups of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic, as defined herein, including HC(O)-, alkyl-C(O)-, substituted alkyl-C(O)-, alkenyl-C(O)-, substituted alkenyl-C(O)-, alkynyl-C(O)-, substituted alkynyl-C(O)-, cycloalkyl-C(O)-, substituted cycloalkyl-C(O)-, cycloalkenyl-C(O)-, substituted cycloalkenyl-C(O)-, aryl-C(O)-, substituted aryl-C(O)-, heteroaryl-C(O)-, substituted heteroaryl-C(O)-, heterocyclyl-C(O)-, and substituted heterocyclyl-C(O)-. For example, an acyl group is the "acetyl" group CH3C(O)-.

[0039] "Acylamino" is R 20 The elements are hydrogen or alkyl, and alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic are as defined herein, -NR 20 C(O)alkyl, -NR 20 C(O) substituted alkyl, NR 20 C(O) cycloalkyl, -NR 20 C(O) substituted cycloalkyl, -NR 20 C(O)cycloalkenyl, -NR 20 C(O)-substituted cycloalkenyl, -NR 20 C(O) alkenyl, -NR 20 C(O) substituted alkenyl, -NR 20 C(O)alkynyl, -NR 20 C(O) substituted alkynyl, -NR 20 C(O)aryl, -NR 20 C(O) substituted aryl, -NR 20C(O) heteroaryl, -NR 20 C(O) substituted heteroaryl, -NR 20 C(O) heterocyclic and -NR 20 This refers to the group in a C(O) substituted heterocyclic structure.

[0040] The terms "aminocarbonyl" or "aminoacyl" are R 21 and R 22 However, independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic, R 21 and R 22 However, they optionally bond together with the nitrogen to which they are attached to form heterocyclic or substituted heterocyclic groups, such as alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic groups as defined herein, -C(O)NR 21 R 22 It refers to the base.

[0041] "Aminocarbonylamino" is R 21 , R 22 , and R 23 However, independently selected from hydrogen, alkyl, aryl, or cycloalkyl, two R groups bond to form a heterocyclyl group, -NR 21 C(O)NR 22 R 23 It refers to the base.

[0042] The term "alkoxycarbonylamino" refers to an -NRC(O)OR group in which each R is independently hydrogen, alkyl, substituted alkyl, aryl, heteroaryl, or heterocyclyl, and alkyl, substituted alkyl, aryl, heteroaryl, and heterocyclyl are as defined herein.

[0043] The term "acyloxy" refers to the groups of alkyl-C(O)O-, substituted alkyl-C(O)O-, cycloalkyl-C(O)O-, substituted cycloalkyl-C(O)O-, aryl-C(O)O-, heteroaryl-C(O)O-, and heterocyclyl-C(O)O-, as defined herein.

[0044] "Aminosulfonyl" is R 21 and R 22 However, independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic, R 21 and R 22 However, optionally, they bond together with the nitrogen to which they are bonded to form heterocyclic or substituted heterocyclic groups, where alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic groups are as defined herein, -SO2NR 21 R 22 It refers to the base.

[0045] "Sulfonylamino" is R 21 and R 22However, independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic, R 21 and R 22 However, they optionally bond together with the nitrogen to which they are attached to form heterocyclic or substituted heterocyclic groups, such as alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic groups, as defined herein, -NR 21 SO2R 22 It refers to.

[0046] "Aryl" or "Ar" refers to a monovalent aromatic carbocyclic group consisting of 6 to 18 carbon atoms forming a single ring (such as that found in the phenyl group), or a ring system having multiple fused rings, where the fused ring may or may not be aromatic, but the bonding site is through an atom of the aromatic ring (examples of such aromatic ring systems include naphthyl, anthryl, and indanyl). Examples of this term include phenyl and naphthyl. Unless otherwise restricted by the definition of aryl substituents, such aryl groups may be optionally substituted with 1 to 5 substituents, or 1 to 3 substituents, selected from acyloxy, hydroxy, thiol, acyl, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, substituted alkyl, substituted alkoxy, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted cycloalkenyl, amino, substituted amino, aminoacyl, acylamino, alkaryl, aryloxy, azide, carboxyl, carboxylalkyl, cyano, halogen, nitro, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclooxy, aminoacyloxy, oxyacylamino, thioalkoxy, substituted thioalkoxy, thioaryloxy, thioheteroaryloxy, -SO-alkyl, -SO-substituted alkyl, -SO-aryl, -SO-heteroaryl, -SO2-alkyl, -SO2-substituted alkyl, -SO2-aryl, -SO2-heteroaryl, and trihalomethyl. In such cases, an aryl group substituted with one to five substituents (as described herein, for example) is referred to as a "substituted aryl."

[0047] "Aryloxy" refers to an -O-aryl group in which the aryl is as defined herein and also contains an optionally substituted aryl group as defined herein, including, for example, phenoxy and naphthoxy.

[0048] "Amino" refers to the -NH2 group.

[0049] The term "substituted amino" refers to an -NRR group in which each R is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, cycloalkenyl, substituted cycloalkenyl, alkynyl, substituted alkynyl, aryl, heteroaryl, and heterocyclyl, provided that at least one R is not hydrogen.

[0050] The term "azide" refers to the -N3 group.

[0051] "Carboxyl," "carboxy," or "carboxylate" refers to -CO2H or a salt thereof.

[0052] The terms "carboxyl ester" or "carboxyester," or "carboxyalkyl" or "carboxylalkyl" are defined as alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic are as defined herein, -C(O)O-alkyl, -C(O) This refers to O-substituted alkyl, -C(O)O-alkenyl, -C(O)O-substituted alkenyl, -C(O)O-alkynyl, -C(O)O-substituted alkynyl, -C(O)O-aryl, -C(O)O-substituted aryl, -C(O)O-cycloalkyl, -C(O)O-substituted cycloalkyl, -C(O)O-cycloalkenyl, -C(O)O-substituted cycloalkenyl, -C(O)O-heteroaryl, -C(O)O-substituted heteroaryl, -C(O)O-heterocyclic, and -C(O)O-substituted heterocyclic groups.

[0053] "(carboxyl ester)oxy" or "carbonate" is defined as alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic as defined herein, -OC(O)O-alkyl, -OC(O)O-substituted alkyl, -OC(O)O-alkenyl, This refers to the groups of -OC(O)O-substituted alkenyls, -OC(O)O-alkynyls, -OC(O)O-substituted alkynyls, -OC(O)O-aryls, -OC(O)O-substituted aryls, -OC(O)O-cycloalkyls, -OC(O)O-substituted cycloalkyls, -OC(O)O-cycloalkenyls, -OC(O)O-substituted cycloalkenyls, -OC(O)O-substituted cycloalkenyls, -OC(O)O-heteroaryls, -OC(O)O-substituted heteroaryls, -OC(O)O-heterocyclic structures, and -OC(O)O-substituted heterocyclic groups.

[0054] "Cyano" or "nitrile" refers to the -CN group.

[0055] "Cycloalkyl" refers to a cyclic alkyl group with 3 to 10 carbon atoms having a monocyclic ring or a polycyclic ring including fused ring systems, crosslinked ring systems, and spiro ring systems. Suitable examples of cycloalkyl groups include adamantyl, cyclopropyl, cyclobutyl, cyclopentyl, and cyclooctyl. Examples of such cycloalkyl groups include monocyclic structures such as cyclopropyl, cyclobutyl, cyclopentyl, and cyclooctyl, or polycyclic structures such as adamantanyl.

[0056] The term "substituted cycloalkyl" refers to a cycloalkyl group having 1 to 5 substituents, or 1 to 3 substituents, selected from alkyl, substituted alkyl, alkoxy, substituted alkoxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azide, cyano, halogen, hydroxyl, oxo, thioketo, carboxyl, carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substituted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-substituted alkyl, -SO-aryl, -SO-heteroaryl, -SO2-alkyl, -SO2-substituted alkyl, -SO2-aryl, and -SO2-heteroaryl.

[0057] "Cycloalkenyl" refers to a non-aromatic cyclic alkyl group having 3 to 10 carbon atoms, having a single ring or multiple rings and at least one double bond, preferably one to two double bonds.

[0058] The term "substituted cycloalkenyl" refers to a cycloalkenyl group having 1 to 5 substituents or 1 to 3 substituents, selected from alkoxy, substituted alkoxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azide, cyano, halogen, hydroxyl, keto, thioketo, carboxyl, carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substituted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-substituted alkyl, -SO-aryl, -SO-heteroaryl, -SO2-alkyl, -SO2-substituted alkyl, -SO2-aryl, and -SO2-heteroaryl.

[0059] "Cycloalkynyl" refers to a non-aromatic cycloalkyl group consisting of 5 to 10 carbon atoms, having one or more rings and at least one triple bond.

[0060] "Cycloalkoxy" refers to -O-cycloalkyl.

[0061] "Cycloalkenyloxy" refers to -O-cycloalkenyl.

[0062] "Halo" or "halogen" refers to fluoro, chloro, bromo, and iodine compounds.

[0063] "Hydroxy" or "hydroxyl" refers to the -OH group.

[0064] A "heteroaryl" refers to an aromatic group having 1 to 15 carbon atoms, such as 1 to 10 carbon atoms in a ring, and 1 to 10 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur. Such heteroaryl groups may have a single ring (e.g., pyridinyl, imidazolyl, or furyl) or a ring system of multiple fused rings (e.g., groups such as indolidinyl, quinolinyl, benzofuran, benzimidazolyl, or benzothienyl), provided that at least one ring in the ring system is aromatic, and at least one ring in the ring system is aromatic, but the bond site is through an atom of the aromatic ring. In certain embodiments, the nitrogen and / or sulfur ring atoms of the heteroaryl group are optionally oxidized to provide an N-oxide (N→O), sulfinyl, or sulfonyl moiety. Examples of this term include pyridinyl, pyrrolyl, indolyl, thiophenyl, and furanyl. Unless otherwise restricted by the definition of heteroaryl substituents, such heteroaryl groups may be optionally substituted with 1 to 5 substituents, or 1 to 3 substituents, selected from acyloxy, hydroxy, thiol, acyl, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, substituted alkyl, substituted alkoxy, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted cycloalkenyl, amino, substituted amino, aminoacyl, acylamino, alkaryl, aryl, aryloxy, azide, carboxyl, carboxylalkyl, cyano, halogen, nitro, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclooxy, aminoacyloxy, oxyacylamino, thioalkoxy, substituted thioalkoxy, thioaryloxy, thioheteroaryloxy, -SO-alkyl, -SO-substituted alkyl, -SO-aryl, -SO-heteroaryl, -SO2-alkyl, -SO2-substituted alkyl, -SO2-aryl and -SO2-heteroaryl, and trihalomethyl. In such cases, a heteroaryl group substituted with one to five substituents (as described herein, for example) is referred to as a "substituted heteroaryl."

[0065] The term "heteroaralkyl" refers to alkylenes and heteroaryls, which are defined herein as -alkylene-heteroaryl groups. Examples of this term include pyridylmethyl, pyridylethyl, and indolylmethyl.

[0066] "Heteroaryloxy" refers to -O-heteroaryl.

[0067] "Heterocyclic," "heterocyclic," "heterocycloalkyl," and "heterocyclyl" refer to saturated or unsaturated groups having one or more fused rings, including fused-bridged ring systems and spiro-ring systems, and containing 3 to 20 ring atoms, each containing 1 to 10 heteroatoms. These ring atoms are selected from the group consisting of nitrogen, sulfur, or oxygen, and in fused ring systems, one or more of the rings may be cycloalkyl, aryl, or heteroaryl, but the bonding site is through a non-aromatic ring. In certain embodiments, the nitrogen and / or sulfur ring atoms of the heterocyclic group are optionally oxidized to provide an N-oxide, -S(O)-, or -SO2- moiety.

[0068] Examples of heterocyclic and heteroaryl compounds include, but are not limited to, azetidine, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, indidine, isoindole, indole, dihydroindole, indazole, purine, quinoridine, isoquinoline, quinoline, phthalazine, naphthylpyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carborin, phenanthridine, acridine, phenanthroline, isothiazole, and phenazine. Examples include isoxazole, phenoxazine, phenothiazine, imidazolidine, imidazoline, piperidine, piperazine, indoline, phthalimide, 1,2,3,4-tetrahydroisoquinoline, 4,5,6,7-tetrahydrobenzo[b]thiophene, thiazole, thiazolidine, thiophene, benzo[b]thiophenol, morpholinyl, thiomorpholinyl (also called thiamorpholinyl), 1,1-dioxothiomorpholinyl, piperidinyl, pyrrolidine, and tetrahydrofuranil.

[0069] Unless otherwise restricted by the definition of heterocyclic substituents, such heterocyclic groups may be optionally substituted with 1 to 5 or 1 to 3 substituents selected from alkoxy, substituted alkoxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, acyl, acylamino, acyloxy, amino, substituted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azide, cyano, halogen, hydroxyl, oxo, thioketo, carboxyl, carboxylalkyl, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol, thioalkoxy, substituted thioalkoxy, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-substituted alkyl, -SO-aryl, -SO-heteroaryl, -SO2-alkyl, -SO2-substituted alkyl, -SO2-aryl, -SO2-heteroaryl, and condensed heterocyclic groups.

[0070] "Heterocyclyloxy" refers to the -O-heterocyclyl group.

[0071] The term "heterocyclilthio" refers to a heterocyclic -S- group.

[0072] The term "heterocyclene" refers to a diradical group formed from a heterocycle, as defined herein.

[0073] The term "hydroxyamino" refers to the -NHOH group.

[0074] "Nitro" refers to the -NO2 group.

[0075] "Oxo" refers to an atom (=O).

[0076] "Sulfonyl" refers to the groups of SO2-alkyl, SO2-substituted alkyl, SO2-alkenyl, SO2-substituted alkenyl, SO2-cycloalkyl, SO2-substituted cycloalkyl, SO2-substituted cycloalkyl, SO2-cycloalkenyl, SO2-substituted cycloalkenyl, SO2-aryl, SO2-substituted aryl, SO2-substituted heteroaryl, SO2-substituted heteroaryl, SO2-heterocyclic, and SO2-substituted heterocyclic, as defined herein. Examples of sulfonyls include methyl-SO2-, phenyl-SO2-, and 4-methylphenyl-SO2-.

[0077] "Sulfonyloxy" refers to groups of the -OSO2-alkyl, OSO2-substituted alkyl, OSO2-alkenyl, OSO2-substituted alkenyl, OSO2-substituted alkenyl, OSO2-cycloalkyl, OSO2-substituted cycloalkyl, OSO2-substituted cycloalkyl, OSO2-cycloalkenyl, OSO2-substituted cycloalkenyl, OSO2-substituted aryl, OSO2-substituted heteroaryl, OSO2-substituted heteroaryl, OSO2-heterocyclic, and OSO2-substituted heterocyclic groups, as defined herein.

[0078] The term "aminocarbonyloxy" refers to an -OC(O)NRR group in which each R is independently hydrogen, alkyl, substituted alkyl, aryl, heteroaryl, or heterocyclic, and alkyl, substituted alkyl, aryl, heteroaryl, and heterocyclic are as defined herein.

[0079] "Thiol" refers to the -SH group.

[0080] The terms "thioxo" or "thioketo" refer to an atom (=S).

[0081] The terms "alkylthio" or "thioalkoxy" refer to an -S-alkyl group as defined herein. In certain embodiments, sulfur may be oxidized to -S(O)-. The sulfoxide may exist as one or more stereoisomers.

[0082] The term "substituted thioalkoxy" refers to an -S-substituted alkyl group.

[0083] The term "thioaryloxy" refers to an aryl-S-group as defined herein, wherein the aryl group is optionally a substituted aryl group as defined herein.

[0084] The term "thioheteroaryloxy" refers to a heteroaryl-S-group as defined herein, in which the heteroaryl group optionally includes a substituted heteroaryl group as defined herein.

[0085] The term "thioheterocyclooxy" refers to a heterocyclyl-S-group as defined herein, in which the heterocyclyl group optionally includes a substituted heterocyclyl group as defined herein.

[0086] In addition to the disclosures herein, the term “substituted” may also mean, when used to modify a given group or radical, that one or more hydrogen atoms of the given group or radical are replaced, each independently of one another, with substituents that are the same as or different from those defined below.

[0087] With respect to the individual terms herein, in addition to the bases disclosed, one or more hydrogen atoms on a saturated carbon atom of a specified group or radical (any two hydrogen atoms on a single carbon atom = O, = NR) 70 、=N-OR 70 The substituents to replace (which can be replaced with =N2 or =S) are R unless otherwise specified. 60 However, selected from the group consisting of optionally substituted alkyl, cycloalkyl, heteroalkyl, heterocycloalkylalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl, each R 70 However, independently, hydrogen or R 60 And each R 80 However, independently, R 70 or, two R's 80’may optionally include the same or different additional 1 to 4 heteroatoms selected from the group consisting of O, N, and S together with the nitrogen to which they are attached to form a 5-, 6-, or 7-membered heterocycloalkyl, and their N may have a -H or C1-C3 alkyl substituent, each M + is a counterion having a net single positive charge, -R 60 halo, =O, -OR 70 -SR 70 -NR 80 R 80 trihalomethyl, -CN, -OCN, -SCN, -NO, -NO2, =N2, -N3, -SO2R 70 -SO2O - M + -SO2OR 70 -OSO2R 70 -OSO2O - M + -OSO2OR 70 -P(O)(O - )2(M + )2, -P(O)(OR 70 )O - M + -P(O)(OR 70 )2, -C(O)R 70 -C(S)R 70 -C(NR 70 )R 70 -C(O)O - M + -C(O)OR 70 -C(S)OR 70 -C(O)NR 80 R 80 -C(NR 70 )NR 80 R 80 -OC(O)R 70 -OC(S)R 70 -OC(O)O - M + -OC(O)OR 70 -OC(S)OR 70 -NR 70 C(O)R 70 -NR 70 [[ID=8)4]]C(S)R 70 -NR 70CO2 - M + , -NR 70 CO2R 70 , -NR 70 C(S)OR 70 , -NR 70 C(O)NR 80 R 80 , -NR 70 C(NR 70 )R 70 , and -NR 70 C(NR 70 )NR 80 R 80 Each M + K is independent, for example, + kaNa + Li + Alkaline ions such as + N(R 60 ) Ammonium ions such as 4, or [Ca 2+ ] 0.5 [Mg 2+ ] 0.5 , or [Ba 2+ ] 0.5 These could be alkaline earth ions such as (the subscript 0.5 means that one of the counterions of such a divalent alkaline earth ion may be the ionized form of the compound of the invention, and the other counterion may be the ionized form of a chloride or the like, or that two ionized compounds disclosed herein may function as counterions of such a divalent alkaline earth ion, or that the biionized compound of the invention may function as a counterion of such a divalent alkaline earth ion). As a specific example, -NR 80 R 80 This means that it includes -NH2, -NH-alkyl, N-pyrrolidinyl, N-piperazinyl, 4N-methylpiperazin-1-yl, and N-morpholinyl.

[0088] In addition to the disclosures herein, the substituents of hydrogen on the unsaturated carbon atoms of “substituted” alkenes, alkynes, aryls, and heteroaryl groups are R unless otherwise specified. 60 , R 70 , R 80 , and M +However, as previously defined, in the case of substituted alkenes or alkynes, the substituent is -O - M + , -OR 70 , -SR 70 , or -S - M + -R 60 Hello, -O - M + , -OR 70 , -SR 70 , -S - M + , -NR 80 R 80 , trihalomethyl, -CF3, -CN, -OCN, -SCN, -NO, -NO2, -N3, -SO2R 70 , -SO3 - M + , -SO3R 70 , -OSO2R 70 , -OSO3 - M + -OSO3R 70 , -PO3 -2 (M + )2, -P(O)(OR 70 )O - M + , -P(O)(OR 70 )2, -C(O)R 70 ,-C(S)R 70 -C(NR 70 )R 70 , -CO2 - M + , -CO2R 70 , -C(S)OR 70 -C(O)NR 80 R 80 -C(NR 70 )NR 80 R 80 -OC(O)R 70 ,-OC(S)R 70 , -OCO2 - M + , -OCO2R 70 , -OC(S)OR 70 , -NR 70 C(O)R 70 , -NR 70 C(S)R 70, -NR 70 CO2 - M + , -NR 70 CO2R 70 , -NR 70 C(S)OR 70 , -NR 70 C(O)NR 80 R 80 , -NR 70 C(NR 70 )R 70 and -NR 70 C(NR 70 )NR 80 R 80 That is the case.

[0089] In addition to the basis of disclosure with respect to individual terms herein, the substituents on the nitrogen atom of "substituted" heteroalkyl and cycloheteralkyl groups are R unless otherwise specified. 60 , R 70 , R 80 , and M + However, as previously defined, -R 60 , -O - M + , -OR 70 , -SR 70 , -S - M + , -NR 80 R 80 , trihalomethyl, -CF3, -CN, -NO, -NO2, -S(O)2R 70 -S(O)2O - M + -S(O)2OR 70 -OS(O)2R 70 -OS(O)2O - M + -OS(O)2OR 70 ,-P(O)(O - )2(M + )2, -P(O)(OR 70 )O - M + , -P(O)(OR 70 )(OR 70 ), -C(O)R 70 ,-C(S)R 70 -C(NR 70 )R70 , -C(O)OR 70 , -C(S)OR 70 -C(O)NR 80 R 80 -C(NR 70 )NR 80 R 80 -OC(O)R 70 ,-OC(S)R 70 -OC(O)OR 70 , -OC(S)OR 70 , -NR 70 C(O)R 70 , -NR 70 C(S)R 70 , -NR 70 C(O)OR 70 , -NR 70 C(S)OR 70 , -NR 70 C(O)NR 80 R 80 , -NR 70 C(NR 70 )R 70 and -NR 70 C(NR 70 )NR 80 R 80 That is the case.

[0090] In addition to the disclosures herein, in certain embodiments, the substituted group has one, two, three, or four substituents, one, two, or three substituents, one or two substituents, or one substituent.

[0091] Unless otherwise indicated, the nomenclature of substituents not explicitly defined herein is reached by naming from the terminal portion of the functional group toward the bond point, followed by the adjacent functional group. For example, the substituent "arylalkyloxycarbonyl" refers to the (aryl)-(alkyl)-OC(O)- group.

[0092] With respect to any of the groups disclosed herein that contain one or more substituents, it is understood that such groups naturally do not contain any substitutions or substitution patterns that are sterically unfeasible and / or synthetically unfeasible. In addition, the compounds of the subject matter include all stereochemical isomers resulting from the substitutions of these compounds.

[0093] "Stereoisomers" refer to compounds that have the same atomic bonding but different atomic arrangements in space. Examples of stereoisomers include cis-trans isomers, E and Z isomers, enantiomers, and diastereomers.

[0094] The terms “its salts, solvates, or stereoisomers” will be understood to include all permutations of the salts, solvates, and stereoisomers, such as solvates of pharmaceutically acceptable salts of the stereoisomers of the compound in question. The terms “its salts” will be understood to include all permutations of the salts. The terms “its pharmaceutically acceptable salts” will be understood to include all permutations of the salts. The terms “its solvates” will be understood to include all permutations of the solvates. The terms “its stereoisomers” will be understood to include all permutations of the stereoisomers. The terms “its tautomers” will be understood to include all permutations of the tautomers. Thus, for example, this would include solvates of pharmaceutically acceptable salts of tautomers of the stereoisomers of the compound in question.

[0095] As used herein, the term “isolated” means describing a compound of interest that is in an environment different from the environment in which the compound naturally occurs. “Isolated” means including a compound in a sample in which the compound of interest is substantially concentrated and / or the compound of interest is partially or substantially purified.

[0096] Before further describing the present invention, it should be understood that the present invention is not limited to the specific embodiments described, as such embodiments can naturally vary. It should also be understood that the scope of the present invention is limited only by the appended claims, and that the terms used herein are for the purpose of describing specific embodiments and are not intended to be limiting.

[0097] Where a range of values ​​is provided, unless the context explicitly indicates otherwise, it is understood that each intermediate value between the upper and lower limits, and any other value in that stated range or up to one-tenth of the lower limit of the intermediate value, are included within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller range and are also included within the invention and subject to any specifically excluded limitations of the stated range. If the stated range includes one or both of the limitations, the range excluding one or both of those included limitations is also included in the invention.

[0098] For clarity, it is understood that certain features of an invention described in the context of a separate embodiment may also be provided in combination in a single embodiment. Conversely, for brevity, various features of an invention described in the context of a single embodiment may also be provided separately or in any preferred partial combination. All combinations of embodiments relating to the invention are specifically encompassed by the invention and are disclosed herein to the extent that such combinations encompass subject matter that is, for example, a stable compound (i.e., a compound that can be prepared, isolated, characterized, and tested for biological activity), as if each and all combinations were individually and expressly disclosed. In addition, all partial combinations of various embodiments and their elements (e.g., elements of chemical groups enumerated in embodiments describing such variables) are also specifically encompassed by the invention and are disclosed herein to the extent that each and all such partial combinations are individually and expressly disclosed herein.

[0099] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which the present invention pertains. Any methods and materials similar or equivalent to those described herein may also be used in carrying out or testing the present invention, but the methods and materials of interest are described below. All publications referenced herein are incorporated herein by reference to disclose and describe methods and / or materials relating to the cited publications.

[0100] It should be noted that, as used herein and in the appended claims, the singular forms “a,” “an,” and “the” refer to multiple subjects unless the context clearly indicates otherwise. It should also be noted that claims may be written to exclude any optional elements. Therefore, this statement is intended to function as an antecedent to the use of exclusive terms such as “simply,” “only,” or “negative” limitations relating to the description of elements of the claims.

[0101] For clarity, it is understood that certain features of an invention described in the context of a separate embodiment may also be provided in combination in a single embodiment. Conversely, for brevity, various features of an invention described in the context of a single embodiment may also be provided separately or in any preferred partial combination.

[0102] The publications discussed herein are provided only for disclosures prior to the filing date of this application. Nothing herein should be construed as acknowledging that the present invention does not have prior rights to such disclosures by prior art. Furthermore, the dates of the publications provided may differ from the actual dates of the publications and may need to be verified individually.

[0103] Unless otherwise noted, the methods and techniques of this embodiment are generally carried out in accordance with conventional methods well known in the art and as described in the various general and more specific references cited and discussed throughout this specification. See, for example, Loudon, *Organic Chemistry*, Fourth Edition, New York: Oxford University Press, 2002, pp. 360-361, 1084-1085, and Smith and March, *March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure*, Fifth Edition, Wiley-Interscience, 2001.

[0104] The nomenclature used herein to name the subject compounds is illustrated in the examples herein. Where possible, this nomenclature is generally derived using commercially available AutoNom software (MDL, San Leandro, Calif.).

[0105] Many common references are available that provide generally known chemical synthesis schemes and conditions useful for synthesizing the disclosed compounds (e.g., Smith and March, March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, Fifth Edition, Wiley-Interscience, 2001, or Vogel, A See Textbook of Practical Organic Chemistry, Including Qualitative Organic Analysis, Fourth Edition, New York: Longman, 1978.

[0106] The compounds described herein can be purified by any means known in the art, including chromatographic methods such as high-performance liquid chromatography (HPLC), preparative thin-layer chromatography, flash column chromatography, and ion-exchange chromatography. Any suitable stationary phase, including normal-phase and reverse-phase chromatography, and ionic resins, can be used. See, for example, Introduction to Modern Liquid Chromatography, 2nd Edition, ed. LRSnyder and JJ Kirkland, John Wiley and Sons, 1979, and Thin Layer Chromatography, ed. E. Stahl, Springer-Verlag, New York, 1969.

[0107] During any of the processes for preparing the compounds of this disclosure, it may be necessary and / or desirable to protect any sensitive or reactive group of the relevant molecules. This can be achieved by conventional protecting group means as described in reference books such as TW Greene and PGMWuts, “Protective Groups in Organic Synthesis”, Fourth edition, Wiley, New York 2006. The protecting group can be removed at a convenient subsequent step using methods known in the art.

[0108] The compounds described herein may contain one or more chiral centers and / or double bonds, and therefore may exist as stereoisomers such as double bond isomers (i.e., geometric isomers), enantiomers, or diastereomers. Thus, all possible enantiomers and stereoisomers of a compound, including stereoisomerically pure forms (e.g., geometrically pure, enantiomerically pure, or diastereomerically pure), as well as mixtures of enantiomers and mixtures of stereoisomers, are included in the description of the compounds herein. Mixtures of enantiomers and mixtures of stereoisomers can be broken down into their enantiomers or stereoisomers using separation techniques or chiral synthesis techniques well known to those skilled in the art. Compounds may also exist in several tautomer forms, including enol forms, keto forms, and mixtures thereof. Therefore, the chemical structures shown herein encompass all possible tautomer forms of the exemplified compounds. The described compounds also include isotopically labeled compounds in which one or more atoms have atomic masses different from those conventionally found in nature. Examples of isotopes that can be incorporated into the compounds disclosed herein include, but are not limited to, 2 H, 3 H, 11 C, 13 C, 14 C, 15 N, 18 O, 17 Examples include O. Compounds can exist in solvated forms, including non-solvated and hydrated forms. Generally, compounds can be hydrated or solvated. Certain compounds can exist in multiple crystalline or amorphous forms. Generally, all physical forms are equivalent for the uses intended herein and are intended to be within the scope of this disclosure.

[0109] The embodiments of the disclosure include crystalline solids of 3-palmitoyl-amide-1,2-propanediol (formula I). [ka]

[0110] The term "crystalline" is used herein in its conventional sense to refer to a solid material in which the molecules forming the solid are arranged in a highly ordered microscopic geometric configuration that extends in three dimensions (e.g., forming an ordered lattice structure). In embodiments, the crystalline solids described herein are not amorphous, characterized by an undefined structural order and microscopic configuration lacking a regular geometric arrangement in three dimensions.

[0111] In some embodiments, the crystalline solid of 3-palmitoyl-amide-1,2-propanediol has polymorphic purity of 90% or more, including 95% or more, 97% or more, 99% or more, and 99.9% or more (i.e., exists as polymorphs as demonstrated by X-ray powder diffraction (XRPD) analysis, thermogravimetric analysis (TGA), and differential scanning calorimetry (DSC) analysis, which are detailed below). In some embodiments, the polymorphs of 3-palmitoyl-amide-1,2-propanediol described herein exist in crystalline solid form with 100% purity. In some embodiments, the polymorphs of the crystalline solid of 3-palmitoyl-amide-1,2-propanediol provided herein exhibit improved solubility and reactivity compared to other polymorphs of crystalline 3-palmitoyl-amide-1,2-propanediol and amorphous 3-palmitoyl-amide-1,2-propanediol.

[0112] In some embodiments, polymorphs of crystalline solid 3-palmitoyl-amide-1,2-propanediol exhibit an X-ray powder diffraction (XRPD) pattern containing a peak at approximately 8.25°2θ. The relative intensity of the diffraction peaks in a given crystalline form may vary due to the orientation of the crystal to X-rays, such as from crystal morphology. In some embodiments, the intensity of the X-ray powder diffraction peak at 2θ may vary from crystal to crystal, but the characteristic peak positions of the polymorphs will remain the same. In certain embodiments, polymorphs of crystalline solid 3-palmitoyl-amide-1,2-propanediol have an X-ray powder diffraction (XRPD) pattern containing one or more peaks at approximately 2.75°2θ, approximately 6°2θ, approximately 3.8°2θ, approximately 15°2θ, approximately 26.3°2θ, approximately 30.5°2θ, and approximately 33.1°2θ. In some cases, the crystalline solid polymorphs of 3-palmitoyl-amide-1,2-propanediol provided herein are characterized by a single weight loss step by thermogravimetric analysis (TGA). In certain cases, the weight loss step begins at approximately 200.5°C.

[0113] Differential scanning calorimetry (DSC) measures the transition temperature of a crystalline solid when a crystal absorbs or releases heat due to changes in its structure or due to melting. DSC is provided to distinguish between different crystalline forms (e.g., different polymorphs). Different crystalline forms can be identified according to their different characteristic transition temperatures. In some embodiments, the crystalline solid polymorphs of 3-palmitoyl-amide-1,2-propanediol provided herein exhibit a first endothermic state at about 79.3°C and a second endothermic state at about 102.5°C by differential scanning calorimetry (DSC). In these embodiments, the second endothermic state is a single peak endothermic state.

[0114] Methods for preparing polymorphs of crystalline solid 3-palmitoyl-amide-1,2-propanediol are also provided. In a particular embodiment, 3-palmitoyl-amide-1,2-propanediol is contacted with one or more solvents to produce a 3-palmitoyl-amide-1,2-propanediol composition, which is then precipitated to produce a crystalline solid of 3-palmitoyl-amide-1,2-propanediol. In some embodiments, the solvent is a polar solvent. In other embodiments, the solvent is a nonpolar solvent. In other embodiments, the solvent is a mixture of a polar solvent and a nonpolar solvent. The solvents of interest include, but are not limited to, tetrahydrofuran, methyltetrahydrofuran, dichloromethane, isopropyl acetate, ethyl acetate, 1,2-dichloroethane (DCE), dimethylformamide (DMF), acetone, dimethylacetamide, dimethyl sulfoxide (DMSO), acetonitrile, toluene, 2-methylbutan-2-ol (tAmOH), and N-methyl-2-pyrrolidone (NMP), as well as combinations thereof. In some cases, the solvent is selected from tetrahydrofuran, methyltetrahydrofuran, and dichloromethane. In certain specific cases, the solvent is tetrahydrofuran.

[0115] In certain embodiments, 3-palmitoyl-amide-1,2-propanediol is brought into contact with a solvent in the presence of a base. In some cases, the base is an organic base. Examples of organic bases that can be used, but are not limited to, include triethylamine, triethanolamine, ammonia, arginine, benzathine, ethylenediamine, meglumine, procaine, N-methylglucamine, piperazine, tromethamine, N,N'-dibenzylethylenediamine, chloroprocaine, diethanolamine, ethanolamine, diisopropylamine, diisopropylethylamine, 1,8-bis(dimethylamino)naphthalene (proton sponge), imidazole, 1,8-diazabicyclo[5.4.0]undeca-7-ene (DBU), 2,4,6-trimethylpyridine (collidine), potassium carbonate, sodium methoxide, tetramethylethylenediamine (TMEDA), and dimethylaminoethanol. In some cases, the base is selected from tetramethylethylenediamine (TMEDA), 1,8-bis(dimethylamino)naphthalene (proton sponge), and triethylamine. In certain cases, the base is triethylamine. The amount of base to contact with 3-palmitoyl-amide-1,2-propanediol can vary in the range of 1 to 4 equivalents of base, such as 1.5 to 3.5 equivalents relative to 3-palmitoyl-amide-1,2-propanediol, and including about 3 equivalents of base relative to 3-palmitoyl-amide-1,2-propanediol.

[0116] To precipitate a crystalline solid of 3-palmitoyl-amide-1,2-propanediol, a 3-palmitoyl-amide-1,2-propanediol solvent composition (with or without a base) can be first heated to produce a heated 3-palmitoyl-amide-1,2-propanediol solvent composition, which can then be cooled to form a crystalline solid of 3-palmitoyl-amide-1,2-propanediol. The 3-palmitoyl-amide-1,2-propanediol solvent composition can be heated to temperatures in the range of 10°C to 60°C, including 15°C to 55°C, 25°C to 55°C, and up to 50°C. The heated composition can be maintained at high temperatures for varying durations, including 1 minute or more, 2 minutes or more, 5 minutes or more, 10 minutes or more, 15 minutes or more, 30 minutes or more, and 60 minutes or more. In certain embodiments, the 3-palmitoyl-amide-1,2-propanediol solvent is heated to a temperature sufficient to solubilize 3-palmitoyl-amide-1,2-propanediol in the solvent. All or part of the 3-palmitoyl-amide-1,2-propanediol can be solubilized in the solvent, such as 25% or more by weight, including 50% or more by weight of 3-palmitoyl-amide-1,2-propanediol, 75% or more by weight, 90% or more by weight, 95% or more by weight, 97% or more by weight, and 99% or more by weight (for example, the 3-palmitoyl-amide-1,2-propanediol solvent composition may range from a clear solution to a slurry composition when examined with the naked eye).

[0117] In some embodiments, the crystalline solid of 3-palmitoyl-amide-1,2-propanediol is precipitated by cooling a heated 3-palmitoyl-amide-1,2-propanediol solvent composition. The composition may be cooled to temperatures ranging from 20°C to 40°C, including 15°C to 35°C and about 30°C. In certain embodiments, the method involves precipitating the crystalline solid of 3-palmitoyl-amide-1,2-propanediol by removing a certain amount of solvent from the composition, such as by rotary evaporation or under an inert gas (N2 or argon).

[0118] In certain embodiments, the crystalline solid of 3-palmitoyl-amide-1,2-propanediol can be isolated by filtration (e.g., vacuum filtration), or the solvent can be removed by heating or rotational evaporation. In certain embodiments, the crystalline solid of 3-palmitoyl-amide-1,2-propanediol can be isolated by drying under a nitrogen atmosphere or vacuum at room temperature.

[0119] The embodiments of the disclosure also include crystalline solids of 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane (formula III). [ka]

[0120] (wherein DMTr is dimethoxytriphenylmethyl). In certain cases, the crystalline solid of 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane is a single crystal of 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane. The term "single crystal" is used herein in its conventional sense, referring to a single-crystalline solid in which the crystal lattice of the entire sample is grain-boundless, continuous with the edges of the sample, and unbroken. In certain embodiments, the single crystal of interest is a single-crystalline solid of 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane of sufficient size and quality for X-ray crystallography (XRC) and X-ray crystallography.

[0121] In some embodiments, the crystalline solid of 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane has a purity of 90% or more, including 95% or more, 97% or more, 99% or more, and 99.9% or more (e.g., a single crystal of 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane). In some embodiments, 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane is present in the crystalline solid with 100% purity. In some embodiments, the crystalline solid form of 3-palmitoylamide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane provided herein (e.g., single crystals of 3-palmitoylamide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane) exhibits improved solubility and reactivity compared to other crystalline forms (e.g., powder) or amorphous solid forms of 3-palmitoylamide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane.

[0122] The crystalline solid of 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane according to the embodiments is in monoclinic form. Each unit cell in the crystalline solid contains two different conformations of 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane, such as the bent conformation and the linear conformation. In the embodiments, each conformation of 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane (bent and linear) is present in the unit cell in a 1:1 ratio. Each unit cell in the crystalline solid contains four molecules of 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane. In some embodiments, the unit cell has dimensions of about 8.44 Å × about 26.56 Å × about 10.06 Å, and the volume of the unit cell is about 2254.8 Å. 3 The subject, 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenyl ether-propane crystalline solid, has a concentration of approximately 1.2 g / cm³. 3 ~Approx. 1.3g / cm3 It has a density and a purity of 95% or more.

[0123] Methods for preparing crystalline solids (e.g., single crystals) of 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane are also provided. In a particular embodiment, 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane is contacted with one or more solvents to produce a 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane composition, which is then precipitated to produce crystalline solids of 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane, such as one or more single crystals of 3-palmitoyl-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane.

[0124] In some embodiments, the solvent is a polar solvent. In other embodiments, the solvent is a nonpolar solvent. In other embodiments, the solvent is a mixture of a polar solvent and a nonpolar solvent. The solvent of choice is not limited to, but other solvents include methanol, ethanol, propanol, isopropanol, n-butanol, isobutanol, t-butanol, dichloromethane, trichloromethane, carbon tetrachloride, 1,4-dioxane, acetone, butanone, pentanone, cyclopentanone, hexanone, cyclohexanone, tetrahydrofuran, acetonitrile, benzene, toluene, xylene, N,N-dimethylformamide, N,N-dimethylacetamide, 2-methylbutan-2-ol (tAmOH), dimethyl sulfoxide, pentane, hexane, heptane, and octanane. In certain embodiments, the solvent is a mixture of dichloromethane and pentane.

[0125] To precipitate the crystalline solid 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane, first, the 3-palmitoyl-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane solvent composition can be heated to produce a heated 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane solvent composition, which can then be cooled to form the crystalline solid 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane. The 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane solvent composition can be heated to temperatures in the range of 10°C to 60°C, including 15°C to 55°C, 25°C to 55°C, and up to 50°C. The heated composition may be maintained at a high temperature for a varying duration, including, for more than 1 minute, more than 2 minutes, more than 5 minutes, more than 10 minutes, more than 15 minutes, more than 30 minutes, and more than 60 minutes. In certain embodiments, the 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane solvent is heated to a temperature sufficient to solubilize the 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane in the solvent.

[0126] In other embodiments, the crystalline solid of 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane is precipitated by cooling a heated 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane solvent composition. The composition may be cooled to temperatures of -20°C to 20°C, including -19°C to 19°C, -18°C to 18°C, -17°C to 17°C, -16°C to 16°C, -15°C to 15°C, -14°C to 14°C, -13°C to 13°C, -12°C to 12°C, -11°C to 11°C, and -10°C to 10°C. In certain embodiments, the method includes precipitating the crystalline solid of 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane by removing the solvent from the composition, such as by rotary evaporation or under an inert gas (N2 or argon).

[0127] The crystalline solid of 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane can be isolated by filtration (e.g., vacuum filtration), or the solvent can be removed by heating or rotational evaporation. In certain embodiments, the crystalline solid of 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane is isolated by drying under a nitrogen atmosphere or vacuum at room temperature.

[0128] A method for preparing 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane from 3-palmitoyl-amide-1,2-propanediol is also described. In the implementation of the method of the subject according to a particular embodiment, a solvent is contacted with a crystalline solid of 3-palmitoyl-amide-1,2-propanediol to produce a precursor composition, and the precursor composition is contacted with a composition containing dimethoxytriphenylmethyl chloride to produce a composition having 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane.

[0129] In embodiments, the solvent of choice may include, but is not limited to, tetrahydrofuran, methyltetrahydrofuran, dichloromethane, isopropyl acetate (iPrOAc), ethyl acetate, 1,2-dichloroethane (DCE), dimethylformamide (DMF), acetone, dimethyl sulfoxide (DMSO), acetonitrile, toluene, 2-methylbutan-2-ol (tAmOH), N-methyl-2-pyrrolidone (NMP), or combinations thereof. In some cases, the solvent is selected from tetrahydrofuran, methyltetrahydrofuran, dichloromethane, isopropyl acetate, acetonitrile, toluene, 2-methylbutan-2-ol (tAmOH), and N-methyl-2-pyrrolidone (NMP). In certain specific cases, the solvent is selected from methyltetrahydrofuran, tetrahydrofuran, and dichloromethane.

[0130] In some embodiments, the precursor composition includes an additive. For example, the additive may be calcium oxide, magnesium oxide, boric acid, tetra-n-butylammonium fluoride (TBAF), 4-dimethylaminopyridine (DMAP), copper chloride (CuCl2), ytterbium(III) chloride (YbCl3), or 1,4-diazabicyclo[2.2.2]octane (DABCO). In some cases, the additive is selected from tetra-n-butylammonium fluoride (TBAF), magnesium oxide, and boric acid. In certain specific cases, the additive is magnesium oxide. The amount of the additive in the precursor composition may vary in the range of 0.05 to 1 equivalent of the additive relative to 3-palmitoyl-amide-1,2-propanediol, such as 0.1 to 0.5 equivalents and including about 0.3 equivalents of the additive.

[0131] In some embodiments, the precursor composition is further contacted with a base. In certain cases, the base is an organic base. In some embodiments, the precursor composition is contacted with a protecting group in the presence of a base selected from 1,8-bis(dimethylamino)naphthalene (proton sponge), imidazole, 1,8-diazabicyclo[5.4.0]undeca-7-ene (DBU), 2,4,6-trimethylpyridine (collidine), triethylamine (TEA), potassium carbonate, sodium methoxide, tetramethylethylenediamine (TMEDA), dimethylaminoethanol, and combinations thereof. In some cases, the base is selected from 1,8-bis(dimethylamino)naphthalene (proton sponge), tetramethylethylenediamine (TMEDA), and triethylamine (TEA). In certain cases, the base is triethylamine.

[0132] The amount of base to be contacted with the 3-palmitoyl-amide-1,2-propanediol precursor composition can vary in the range of 0.5 to 3.5 equivalents of base, including 0.75 to 1.95 equivalents, 1 to 1.9 equivalents, 1.1 to 1.85 equivalents, 1.15 to 1.80 equivalents, 1.25 to 1.75 equivalents, and contacting 3-palmitoyl-amide-1,2-propanediol with 1.5 equivalents of base.

[0133] In some embodiments, the precursor composition is formed and maintained at ambient temperature. In other embodiments, the precursor composition is formed and maintained at high temperatures, such as about 30°C, including 25°C to 40°C, 27.5°C to 45°C, and 30°C to 35°C. In certain embodiments, the precursor composition is formed at a first temperature and then changed to a second temperature. In one example, the precursor composition is formed at ambient temperature and then changed to a high temperature of about 30°C, such as 25°C to 40°C, including 27.5°C to 45°C and 30°C to 35°C. In another example, the precursor composition is formed at a high temperature (e.g., about 50°C or higher), cooled to a lower temperature (e.g., about 30°C), and then the precursor composition is brought into contact with the protecting group.

[0134] In one embodiment, the precursor composition is brought into contact with a hydroxyl protecting group to produce 3-palmitoylamide)-2-hydroxy-1-(protected hydroxy)-propane. The hydroxyl protecting group may vary, and in certain cases, the hydroxyl protecting group may include, but is not limited to, 1) alkyl ether type protecting groups such as alkyl ethers, allyl ethers, triphenyl methyl ether, dimethoxy-triphenyl methyl ether, benzyl ether, or p-methoxybenzyl ether protecting groups, and 2) ester and carbonate type protecting groups such as acetates, chloroacetates, dichloroacetates, trichloroacetates, trifluoroacetates, pivaloates, benzoates, p-methoxybenzoates, p-bromobenzoates, methyl carbonate, 9-(fluorenylmethyl) carbonate (Fmoc), allyl carbonate (Alloc), 2,2,2-trichloroethyl carbonate (Troc), 2-(trimethylsilyl)ethyl carbonate (Teoc), benzyl carbonate (Cbz), t-butyl carbonate (Boc), or dimethylthiocarbmate (thiocarbmate) (DMTC) protecting groups. 3) Acetal-type protecting groups such as methoxymethyl ether (MOM), benzyloxymethyl ether (BOM), 2,2,2-trichloroethoxymethyl ether, 2-methoxymethyl ether (MEM), methylthiomethyl ether (MTM), p-methoxybenzyloxymethyl ether (PMBM), 2-(trimethylsilyl)ethoxymethyl ether (SEM), and tetrahydropyranyl ether (THP) protecting group; and 2) silyl ether-type protecting groups such as trimethylsilyl (TMS), triethylsilyl (TES), isopropyldimethylsilyl (IPDMS), diethylisopropylsilyl (DEIPS), t-butyldimethylsilyl (TBS), t-butyldiphenylsilyl (TBDPS), triisopropylsilyl (TIPS), tetraisopropyldisiloxanylidene (TIPDS), or di-t-butylsilylene (DTBS) protecting group. In some embodiments, the hydroxyl protecting group is a dimethoxy-triphenylmethyl protecting group.

[0135] The amount of hydroxyl protecting group to be contacted with the precursor composition may vary in the range of 0.5 to 2 equivalents of additives, such as 0.75 to 1.5 equivalents relative to 3-palmitoyl-amide-1,2-propanediol, and approximately 1.4 equivalents of hydroxyl protecting groups relative to 3-palmitoyl-amide-1,2-propanediol.

[0136] In some embodiments, the 3-palmitoyl-amide-1,2-propanediol used in a method for preparing 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane is a crystalline solid of 3-palmitoyl-amide-1,2-propanediol. In certain embodiments, the 3-palmitoyl-amide-1,2-propanediol is a polymorph of a crystalline solid 3-palmitoyl-amide-1,2-propanediol that exhibits an X-ray powder diffraction (XRPD) pattern having one or more peaks at about 2.75°2θ, about 6°2θ, about 3.8°2θ, about 8.25°2θ, about 15°2θ, about 26.3°2θ, about 30.5°2θ, and about 33.1°2θ.

[0137] The components used in each step of the method of the subject may, as desired, be a purified composition or a crude composition. The term “purified” is used in its conventional sense to refer to a composition that has undergone at least some isolation or purification process, such as filtration of the reaction mixture or an aqueous workup. In certain cases, purification may include liquid chromatography, recrystallization, distillation (e.g., azeotropic distillation), or other types of compound purification. In some embodiments, the reaction mixture is used in subsequent steps of the method herein as a crude composition that has not undergone purification or other workup of the reaction mixture. In certain cases, the crude composition reaction mixture may be subjected to high-performance liquid chromatography (HPLC), proton nuclear magnetic resonance spectroscopy, etc. 1The target compound is contained in a sufficiently pure state, such as containing the target compound with a purity of 90% or higher, including 95% or higher, 97% or higher, and 99% or higher, as determined by 1H NMR, or a combination thereof.

[0138] Disclosure method The embodiments of the subject matter described herein may be useful on their own or in combination with one or more other embodiments or models. Certain non-limiting embodiments of the disclosures numbered 1 to 66 are provided below without limiting the description. As will be apparent to those skilled in the art upon reading this disclosure, each of the individually numbered embodiments may be used with or combined with any of the preceding or succeeding individually numbered embodiments. This is intended to support the underlying assumptions of all such combinations of embodiments, and is not limited to the combinations of embodiments expressly provided below.

[0139] 1. A crystalline solid of the compound of formula I. [ka] 2. A crystalline solid according to embodiment 1, having an X-ray powder diffraction (XRPD) pattern with a peak at approximately 8.25°2θ. 3. A crystalline solid according to embodiment 1 or 2, having an XRPD pattern that includes one or more peaks at approximately 2.75°2θ, approximately 6°2θ, approximately 3.8°2θ, approximately 15°2θ, approximately 26.3°2θ, approximately 30.5°2θ, and approximately 33.1°2θ. 4. A crystalline solid according to any one of embodiments 1 to 3, wherein thermogravimetric analysis (TGA) of the crystalline solid is characterized by a single weight loss step. 5. The crystalline solid according to embodiment 4, wherein the weight loss step begins at approximately 200.5°C. 6. A crystalline solid according to any one of embodiments 1 to 5, having a first endothermic temperature at 79.3°C and a second endothermic temperature at approximately 102.5°C, as determined by differential scanning calorimetry (DSC). 7. The crystalline solid according to embodiment 6, wherein the second endothermic reaction is a single peak endothermic reaction. 8. Solvent of compound I: [ka] By bringing it into contact with, a precursor composition is produced, A method comprising producing a crystalline solid of a compound of formula I from a precursor composition. 9. The method according to embodiment 8, wherein the solvent is selected from the group consisting of tetrahydrofuran, methyltetrahydrofuran, dichloromethane, isopropyl acetate, ethyl acetate, 1,2-dichloroethane (DCE), dimethylformamide (DMF), acetone, dimethylacetamide, dimethyl sulfoxide (DMSO), acetonitrile, toluene, 2-methylbutan-2-ol (tAmOH), and N-methyl-2-pyrrolidone (NMP), and combinations thereof. 10. The method according to embodiment 9, wherein the solvent is selected from tetrahydrofuran, methyltetrahydrofuran, and dichloromethane. 11. The method according to embodiment 10, wherein the solvent is tetrahydrofuran. 12. It is possible to produce a crystalline solid of the compound of formula I. The precursor composition is heated to a temperature of approximately 45°C to approximately 65°C, The method according to any one of embodiments 8 to 11, comprising cooling a heated precursor composition to a temperature of about 25°C to about 35°C to produce a crystalline solid of the compound of formula I. 13. The method according to embodiment 12, wherein producing a crystalline solid of the compound of formula I comprises heating a precursor composition to a temperature of about 50°C and cooling the heated precursor composition to a temperature of about 30°C to produce a crystalline solid of formula I. 14. The method according to any one of embodiments 8 to 13, wherein the compound of formula I is brought into contact with a solvent in the presence of a base. 15. The method according to embodiment 14, wherein the base is triethylamine (TEA). 16. The method according to any one of embodiments 8 to 15, wherein the crystalline solid of the compound of formula I has an X-ray powder diffraction (XRPD) pattern including a peak at approximately 8.25°2θ. 17. The method according to any one of embodiments 8 to 16, wherein a crystalline solid of the compound of formula I has an XRPD pattern including one or more peaks at approximately 2.75°2θ, approximately 6°2θ, approximately 3.8°2θ, approximately 15°2θ, approximately 26.3°2θ, approximately 30.5°2θ, and approximately 33.1°2θ. 18. The method according to any one of embodiments 8 to 17, wherein the crystalline solid of the compound of formula I is characterized by a single weight loss step by thermogravimetric analysis (TGA). 19. The method according to embodiment 18, wherein the weight loss step begins at approximately 200.48°C. 20. The method according to any one of embodiments 8 to 19, wherein a crystalline solid of the compound of formula I exhibits a first endothermic reaction at 79.3°C and a second endothermic reaction at approximately 102.5°C, as determined by differential scanning calorimetry (DSC). 21. The method according to embodiment 20, wherein the second endothermic reaction is a single peak endothermic reaction. 22. Solvent of compound of formula I: [ka] The process involves contacting a crystalline solid with a precursor composition to produce a precursor composition, The precursor composition is brought into contact with a composition containing dimethoxytriphenylmethyl chloride to obtain a compound of formula II: [ka] A method comprising producing a composition (wherein DMTr is dimethoxytriphenylmethyl). 23. The method according to embodiment 22, wherein the precursor composition is contacted with dimethoxytriphenylmethyl chloride in the presence of a base. 24. A base in an organic base, the method according to embodiment 23. 25. The method according to embodiment 23, wherein the base is selected from the group consisting of 1,8-bis(dimethylamino)naphthalene (proton sponge), imidazole, 1,8-diazabicyclo[5.4.0]undeca-7-ene (DBU), 2,4,6-trimethylpyridine (collidine), triethylamine (TEA), potassium carbonate, sodium methoxide, tetramethylethylenediamine (TMEDA), and dimethylaminoethanol. 26. The method according to embodiment 23, wherein the base is selected from 1,8-bis(dimethylamino)naphthalene (proton sponge), tetramethylethylenediamine (TMEDA), and triethylamine (TEA). 27. The method according to embodiment 23, wherein the base is triethylamine (TEA). 28. The method according to any one of embodiments 22 to 27, wherein the precursor composition is contacted with dimethoxytriphenylmethyl chloride in the presence of an additive. 29. The method according to embodiment 28, wherein the additive is selected from the group consisting of calcium oxide, magnesium oxide, boric acid, tetra-n-butylammonium fluoride (TBAF), 4-dimethylaminopyridine (DMAP), copper chloride (CuCl2), ytterbium(III) chloride (YbCl3), and 1,4-diazabicyclo[2.2.2]octane (DABCO). 30. The method according to embodiment 29, wherein the additive is selected from tetra-n-butylammonium fluoride (TBAF), magnesium oxide, and boric acid. 31. The method according to embodiment 29, wherein the additive is magnesium oxide. 32. The method according to any one of embodiments 22 to 31, wherein the solvent is selected from the group consisting of tetrahydrofuran, methyltetrahydrofuran, dichloromethane, isopropyl acetate, ethyl acetate, 1,2-dichloroethane (DCE), dimethylformamide (DMF), acetone, dimethyl sulfoxide (DMSO), acetonitrile, toluene, 2-methylbutan-2-ol (tAmOH), and N-methyl-2-pyrrolidone (NMP), and combinations thereof. 33. The method according to embodiment 32, wherein the solvent is selected from tetrahydrofuran, methyltetrahydrofuran, dichloromethane, isopropyl acetate, acetonitrile, toluene, 2-methylbutan-2-ol (tAmOH), and N-methyl-2-pyrrolidone (NMP). 34. The method according to embodiment 32, wherein the solvent is selected from methyltetrahydrofuran, tetrahydrofuran, and dichloromethane. 35. The method according to any one of embodiments 22 to 34, wherein the crystalline solid of the compound of formula I has an X-ray powder diffraction (XRPD) pattern including a peak at approximately 8.25°2θ. 36. The method according to any one of embodiments 22 to 35, wherein a crystalline solid of the compound of formula I has an XRPD pattern including one or more peaks at approximately 2.75°2θ, approximately 6°2θ, approximately 3.8°2θ, approximately 15°2θ, approximately 26.3°2θ, approximately 30.5°2θ, and approximately 33.1°2θ. 37. The method according to any one of embodiments 22 to 36, wherein the crystalline solid of the compound of formula I is characterized by a single weight loss step by thermogravimetric analysis (TGA). 38. The method according to embodiment 37, wherein the weight loss step begins at approximately 200.48°C. 39. The method according to any one of embodiments 22 to 38, wherein a crystalline solid of the compound of formula I exhibits a first endothermic reaction at 79.3°C and a second endothermic reaction at approximately 102.5°C, as determined by differential scanning calorimetry (DSC). 40. The method according to embodiment 39, wherein the second endothermic is a single peak endothermic. 41. Compounds of formula II: [ka] A crystalline solid of (wherein DMTr is dimethoxytriphenylmethyl). 42. The crystalline solid according to embodiment 41, wherein the crystalline solid of formula II is in a monoclinic form. 43. A crystalline solid according to any one of embodiments 40 to 42, wherein each unit cell in the crystalline solid contains two different conformations of the compound of formula II. 44. The crystalline solid according to embodiment 43, wherein each unit cell contains the extended conformation and the bent conformation of the compound of formula II. 45. A crystalline solid according to embodiment 43 or 44, wherein each conformation of the compound of formula II is present in a 1:1 ratio. 46. ​​A crystalline solid according to any one of embodiments 41 to 45, wherein each unit cell of the crystalline solid contains four molecules of the compound of formula II. 47. The crystalline solid according to embodiment 46, wherein the unit cell has dimensions of approximately 8.44 Å × approximately 26.56 Å × approximately 10.06 Å. 48. The unit cell is approximately 2254.8 Å. 3 A crystalline solid according to embodiment 47 having the volume of . 49.About 1.2g / cm 3 ~Approx. 1.3g / cm 3 A crystalline solid according to embodiment 48 having a density of . 50. A crystalline solid according to any one of embodiments 41 to 49, wherein the compound of formula II has a polymorphic purity of 95% or more. 51. Contacting a composition containing one or more solvents with a compound of formula III, [ka] A method comprising forming one or more single crystals of the compound of formula II. 52. The method according to embodiment 51, wherein the composition comprises two different solvents. 53. The method according to embodiment 52, wherein the composition comprises a polar solvent and a nonpolar solvent. 54. The method according to embodiment 53, wherein the polar solvent is dichloromethane. 55. The method according to embodiment 53 or 54, wherein the nonpolar solvent is pentane. 56. The method according to any one of embodiments 51 to 55, wherein the composition is brought into contact with the compound of formula II at a temperature of 10°C to about 75°C. 57. The method according to embodiment 56, wherein the method comprises heating the composition sufficiently to dissolve the compound of formula II, and cooling the heated composition after the compound of formula II has been dissolved. 58. The method according to any one of embodiments 51 to 57, wherein one or more of the formed single crystals are in a monoclinic form. 59. The method according to any one of embodiments 51 to 58, wherein each single crystal contains two different conformations of the compound of formula II. 60. The method according to embodiment 59, wherein each unit cell of the single crystal includes the extended conformation and the bent conformation of the compound of formula II. 61. The method according to embodiment 59 or 60, wherein each conformation of the compound of formula II is present in a 1:1 ratio within each unit cell. 62. The method according to any one of embodiments 51 to 61, wherein each unit cell of the single crystal contains four molecules of the compound of formula II. 63. The method according to embodiment 62, wherein the unit cell has dimensions of approximately 8.44 Å × approximately 26.56 Å × approximately 10.06 Å. 64. The unit cell is approximately 2254.8 Å. 3 The method according to embodiment 63, having the volume of [a certain value]. 65. Each formed single crystal has a density of approximately 1.2 g / cm³. 3 ~Approx. 1.3g / cm 3 The method according to any one of embodiments 51 to 64, having the density of 66. The method according to any one of embodiments 51 to 65, wherein each formed single crystal has a polymorphic purity of 95% or more of the compound of formula II. [Examples]

[0140] The following examples are provided to those skilled in the art to provide a complete disclosure and description of the methods of preparation and use of the present invention and are not intended to limit the scope of what the inventors consider to be the invention, nor are they intended to represent all or only experiments that are performed. Efforts have been made to ensure accuracy with respect to the numerical values ​​used (e.g., quantity, temperature, etc.), but some experimental errors and deviations should be taken into account. Unless otherwise indicated, parts are parts by weight, molecular weight is weight-average molecular weight, temperature is in degrees Celsius, and pressure is approximately atmospheric pressure. "Average" means arithmetic mean. Standard abbreviations, e.g., bp, base pair; kb, kilobase; pl, picoliters; s or sec, seconds; min, minutes; h or hr, hours; aa, amino acid; kb, kilobase; bp, base pair; nt, nucleotide; im, intramuscular; intraperitoneal; sc, subcutaneous, etc. may be used.

[0141] General synthesis procedure Many common references are available that provide generally known chemical synthesis schemes and conditions useful for synthesizing the disclosed compounds (e.g., Smith and March, March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, Fifth Edition, Wiley-Interscience, 2001, or Vogel, A See Textbook of Practical Organic Chemistry, Including Qualitative Organic Analysis, Fourth Edition, New York: Longman, 1978.

[0142] The compounds described herein may be purified by any purification protocol known in the art, including chromatography such as HPLC, preparative thin-layer chromatography, flash column chromatography, and ion-exchange chromatography. Any suitable stationary phase, including normal-phase and reverse-phase chromatography, and ionic resins, may be used. In certain embodiments, the compounds disclosed are purified via silica gel and / or alumina chromatography. See, for example, Introduction to Modern Liquid Chromatography, 2nd Edition, ed. LRSnyder and JJ Kirkland, John Wiley and Sons, 1979, and Thin Layer Chromatography, ed. E. Stahl, Springer-Verlag, New York, 1969.

[0143] During any of the processes for preparing the compound of interest, it may be necessary and / or desirable to protect any sensitive or reactive groups of the relevant molecules. This is illustrated in JFWMcOmie, “Protective Groups in Organic Chemistry”, Plenum Press, London and New York 1973; TW Greene, and PGMWuts, “Protective Groups in Organic Synthesis”, Third edition, Wiley, New York 1999; “The Peptides”; Volume 3 (editors: E. Gross and J. Meienhofer), Academic Press, London and New York 1981; “Methoden der organischen Chemie”, Houben-Weyl, 4 thIt can be achieved by means of conventional protecting groups described in reference books such as the 15th edition, Vol. 15 / I, Georg Thieme Verlag, Stuttgart 1974, H.-D. Jakubke and H. Jescheit, “Aminosauren, Peptide, Proteine”, Verlag Chemie, Weinheim, Deerfield Beach, and Basel 1982, and / or Jochen Lehmann, “Chemie der Kohlenhydrate: Monosaccharide and Derivate”, Georg Thieme Verlag, Stuttgart 1974. The protecting groups can be removed at a convenient subsequent stage using methods known in the art.

[0144] The compounds of the subject can be synthesized via a variety of different synthetic routes using commercially available starting materials and / or starting materials prepared by conventional synthetic methods. Various examples of synthetic routes that can be used to synthesize the compounds disclosed herein are described below.

[0145] Example 1 - Preparation and Analysis of the Crystalline Polymorphs of 3 - Palmitoyl - amido - 1,2 - propanediol The solubility of 3-palmitoyl-amido-1,2-propanediol was screened using various solvents and solvent mixtures. Tetrahydrofuran (THF), 2-methyl-THF, dichloromethane (DCM), N-methyl-2-pyrrolidone (NMP), dimethylacetamide (DMAc), toluene, 2-methylbutan-2-ol (tAmOH), isopropyl acetate (iPrOAc), dimethyl sulfoxide (DMSO), and dimethylformamide (DMF) were identified as solvents for use in the study. The effect of triethylamine on solubility was also evaluated. Triethylamine was shown to have little effect on the solubility of 3-palmitoyl-amido-1,2-propanediol in these solvents. Dimethylacetamide (DMAc), dimethyl sulfoxide (DMSO), and dimethylformamide (DMF) were determined to have moderate solubility of 3-palmitoyl-amido-1,2-propanediol.

[0146] The crystalline solid was identified as a new polymorph of 3-palmitoyl-amido-1,2-propanediol using triethylamine and THF, 2-methyl-THF, or DCM during crystallization induced by heating / cooling. Heating / cooling crystallization includes solubilizing 3-palmitoyl-amido-1,2-propanediol in a THF solution and heating and maintaining the composition at 50 °C overnight. In 2-methyl-THF or DCM, the solution with palmitoyl-amido-1,2-propanediol was heated overnight to 60 °C to form a solution. After cooling the sample to 30 °C, a crystalline solid was formed as a slurry in solutions of THF, 2-methyl-THF, and DCM.

[0147] When the polymorph of 3-palmitoyl-amido-1,2-propanediol formed was used as a substrate in the preparation of 3-palmitoyl-amido-2-hydroxy-1-dimethoxytrityl ether-propane, it exhibited faster solubility and higher reaction selectivity.

[0148] Crystalline solids were analyzed by X-ray powder diffraction (as droplets of slurry), thermogravimetric analysis, differential scanning calorimetry, and nuclear magnetic resonance spectroscopy. Figure 1 shows a comparison of the X-ray powder diffraction (XRPD) peaks of crystalline solids formed from solutions of (b) THF, (c) 2-methyl THF, and (d) DCM with those of (a) the 3-palmitoyl-amide-1,2-propanediol starting material. As shown in Figure 1, the crystalline solids formed from THF, 2-methyl THF, and DCM exhibit different peaks (e.g., at approximately 2.75°2θ, 6°2θ, 3.8°2θ, 8.25°2θ, 15°2θ, 26.3°2θ, 30.5°2θ, and 33.1°2θ) from the 3-palmitoyl-amide-1,2-propanediol starting material.

[0149] Figure 2 shows the thermogravimetric analysis of the crystalline solid formed from a solution of THF. The TGA of the 3-palmitoyl-amide-1,2-propanediol polymorph formed from THF featured a single weight loss step starting at approximately 200.5°C. The graph in Figure 2 also shows the differential scanning calorimetry of the crystalline solid formed from a solution of THF. Figure 2 shows the DSC plot of the 3-palmitoyl-amide-1,2-propanediol polymorph formed from THF, which exhibited two endothermic peaks: a first at approximately 79.9°C and a second at approximately 102.5°C. The second endothermic peak at approximately 102.5°C was a single peak endothermic. Figure 3 shows a comparison of the DSC plots of the 3-palmitoyl-amide-1,2-propanediol polymorph formed from THF with that of the 3-palmitoyl-amide-1,2-propanediol starting material. The 3-palmitoylamide-1,2-propanediol starting material exhibits a first endothermic reaction at approximately 79.3°C and a second endothermic reaction at approximately 105.8°C.

[0150] Example 2-3 Preparation of 3-palmitoylamide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane (compound B) from palmitoylamide-1,2-propanediol (compound A) The reaction between 3-palmitoyl-amide-1,2-propanediol (CMPD-A) and 4,4'-dimethoxytriphenylmethyl chloride was tested in different bases and solvents. Different additives to the reaction mixture were also tested. Table 1 summarizes the reaction products formed: 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane (CMPD-B), 3-palmitoyl-amide-1-hydroxy-2-dimethoxytriphenylmethyl ether-propane (CMPD-B-Reg), and 3-palmitoyl-amide-1,2-dimethoxytriphenylmethyl ether-propane (Bis-DMTr). For each reaction, 3-palmitoyl-amide-1,2-propanediol was packed into a three-necked round-bottom flask containing the solvent at 30°C and stirred for 1 hour. 3.0 equivalents of base were added to the 3-palmitoyl-amide-1,2-propanediol solvent composition and stirred at 30°C. When additives were used, 0.3 equivalents of the additive were brought into contact with the reaction mixture. 1.4 equivalents of 4,4'-dimethoxytriphenylmethyl chloride were added, and the resulting suspension was stirred at 30°C for approximately 17.3 hours. Samples from the reaction mixture were taken periodically (every 2 hours, every 4 hours, etc.), and the reaction products were characterized by HPLC. [Table 1-1] [Table 1-2]

[0151] Example 3 - Preparation of 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane (compound B) from 3-palmitoyl-amide-1,2-propanediol (compound A) using methyl THF and TEA 3-Palmitoyl-amide-1,2-propanediol was packed into a three-necked round-bottom flask containing methyl THF at 30°C to produce a white suspension, which was stirred at 30°C for 1 hour. The flask was equipped with an overhead stirrer, thermocouple, nitrogen inlet, and glass stopper. 3.0 equivalents of triethylamine were added and stirred at 30°C for 0.5 hours. 1.4 equivalents of 4,4'-dimethoxytriphenylmethyl chloride were added all at once to the white suspension. The resulting yellow suspension was stirred at 30°C for 23 hours. The samples were analyzed at 2 hours, 4 hours, 20 hours, and 23 hours to confirm the progress of the tritylation reaction and the formation of any impurities (e.g., undesirable positional isomers and bis-tritylated compounds). After 2 hours of reaction, 3-Palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane was formed in 63.2% yield. The positional isomer impurity, 3-palmitoyl-amide-2-dimethoxytriphenylmethyl ether-1-hydroxy-propane, was formed in a yield of 0.4%, while the bis-tritylated compound was formed in a yield of 7.8%. After 4 hours of reaction, 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane was formed in a yield of 65.8%. The positional isomer impurity, 3-palmitoyl-amide-2-dimethoxytriphenylmethyl ether-1-hydroxy-propane, was formed in a yield of 0.2%, while the yield of the bis-tritylated compound increased to 11.2%. After 20 hours of reaction, 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane was formed in a yield of 62.4%. The positional isomer impurity, 3-palmitoylamide-2-dimethoxytriphenylmethyl ether-1-hydroxy-propane, was formed in a yield of 0.1%, while the yield of the bis-tritylated compound increased to 16.6%. After 23 hours, 3-palmitoylamide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane was formed in a yield of 62.6%. The positional isomer impurity, 3-palmitoylamide-2-dimethoxytriphenylmethyl ether-1-hydroxy-propane, was formed in a yield of 0.1%, while the yield of the bis-tritylated compound was maintained at 16.6%.

[0152] Example 4: Preparation of 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane (compound [compound B]) from 3-palmitoyl-amide-1,2-propanediol (compound A) using methyl-THF and TEA, and magnesium oxide. 3-Palmitoyl-amide-1,2-propanediol and 0.3 equivalents of magnesium oxide were packed into a three-necked round-bottom flask containing methyl THF at 30°C. The flask was equipped with an overhead stirrer, thermocouple, nitrogen inlet, and glass stopper. The white suspension was stirred at 30°C for 1 hour. 3.0 equivalents of triethylamine were added and the mixture was stirred at 30°C for 0.5 hours. 1.4 equivalents of 4,4'-dimethoxytriphenylmethyl chloride were added all at once. The resulting yellowish-green suspension was stirred at 30°C for 23 hours. The samples were analyzed at 2 hours, 4 hours, 20 hours, and 23 hours to confirm the progress of the tritylation reaction and the formation of any impurities (e.g., undesirable positional isomers and bis-tritylated compounds). After 2 hours of reaction, 3-Palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane was formed in 63.2% yield. The positional isomer impurity, 3-palmitoylamide-2-dimethoxytriphenylmethyl ether-1-hydroxypropane, was formed in a yield of 0.4%, while the bis-tritylated compound was formed in a yield of 7.7%. After 4 hours of reaction, 3-palmitoylamide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane was formed in a yield of 65.7%. The positional isomer impurity, 3-palmitoylamide-2-dimethoxytriphenylmethyl ether-1-hydroxypropane, was formed in a yield of 0.3%, while the yield of the bis-tritylated compound increased to 11.0%. After 20 hours of reaction, 3-palmitoylamide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane was formed in a yield of 63.2%. The positional isomer impurity, 3-palmitoylamide-2-dimethoxytriphenylmethyl ether-1-hydroxy-propane, was no longer present, and the yield of the bis-tritylated compound increased to 16.7%. After 23 hours, 3-palmitoylamide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane was formed in a yield of 62.6%.The positional isomer impurity, 3-palmitoylamide-2-dimethoxytriphenylmethyl ether-1-hydroxypropane, was formed in a yield of 0.1%, while the yield of the bis-tritylated compound increased slightly to 16.9%.

[0153] Example 5: Preparation of 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane (compound B) from 3-palmitoyl-amide-1,2-propanediol (compound A) using methyl-THF and TEA, as well as magnesium oxide and heating. 3-Palmitoyl-amido-1,2-propanediol, 0.3 equivalents of magnesium oxide, and 3.0 equivalents of triethylamine were packed into a three-necked round-bottom flask containing methyl THF at ambient temperature. The flask was equipped with an overhead stirrer, a thermocouple, a nitrogen inlet, and a glass stopper. The composition was heated to 48°C to produce a white suspension, which was stirred at 48°C for 1 hour. The composition was further heated to 55°C and stirred for another 1 hour. The reaction mixture was heated again to 60°C and stirred for a further 30 minutes. The reaction mixture was cooled to 30°C over 70 minutes, and 1.4 equivalents of 4,4'-dimethoxytriphenylmethyl chloride were added all at once to the resulting white suspension. The resulting pale green suspension was stirred at 30°C for 23 hours. Samples were analyzed at 2, 4, 20, and 23 hours to confirm the progress of the tritylation reaction and the formation of any impurities (e.g., undesirable positional isomers and bis-tritylated compounds). After 2 hours of reaction, 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane was formed in 67.0% yield. The positional isomer impurity, 3-palmitoyl-amide-2-dimethoxytriphenylmethyl ether-1-hydroxy-propane, was formed in 0.2% yield, and the bis-tritylated compound was formed in 8.3% yield. After 4 hours of reaction, 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane was formed in 66.2% yield. The positional isomer impurity, 3-palmitoylamide-2-dimethoxytriphenylmethyl ether-1-hydroxy-propane, was formed in a yield of 0.1%, and the yield of the bis-tritylated compound increased to 11.6%. After 20 hours of reaction, 3-palmitoylamide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane was formed in a yield of 63.2%. The positional isomer impurity, 3-palmitoylamide-2-dimethoxytriphenylmethyl ether-1-hydroxy-propane, was no longer present, and the yield of the bis-tritylated compound increased to 18.1%. After 23 hours, 3-palmitoylamide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane was formed in a yield of 63.0%.The positional isomer impurity, 3-palmitoylamide-2-dimethoxytriphenylmethyl ether-1-hydroxypropane, was no longer present, and the yield of the bis-tritylated compound increased slightly to 18.2%.

[0154] Example 6-X-ray crystal structure analysis of 3-palmitoylamide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane Single crystals of 3-palmitoylamide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane were produced by recrystallization of compositions of 3-palmitoylamide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane in various solvents and solvent mixtures. Single crystals formed from dichloromethane / pentane were used for X-ray diffraction studies.

[0155] X-ray diffraction was collected from single crystals in their natural form at -100°C. For X-ray crystal structure analysis, monoclinic plate-like specimens with dimensions of approximately 0.080 mm × 0.130 mm × 0.130 mm were used. For Cu radiation (λ=1.54178 Å), a Bruker D8 QUEST single-crystal X-ray diffractometer with a high-brightness IμS3.0 microfocus (50 kV × 1 mA) was used to study the X-ray structure, and a PHOTON II charge-integrating pixel array detector, with its excellent speed, sensitivity, and accuracy, was used for crystal screening / evaluation and diffraction data acquisition. A Cryostream 800 cryogenic device provided sample temperatures from 80 K to 500 K and was used to cool the crystals to 173 K (-100°C). The Bruker APEX3 software suite, including SHELXTL, was used for diffraction experiments for data acquisition and integration, as well as for elucidating, refining, and displaying structural results.

[0156] A total of 1346 frames were collected. The total exposure time was 12.76 hours. The frames were integrated using the Bruker SAINT software package with a narrow frame algorithm. Integration of the data using a triclinic unit cell yielded a total of 30535 reflections for a maximum θ angle of 65.20° (0.85 Å resolution), of which 12077 were independent (mean redundancy 2.528, completeness = 96.7%, Rint = 3.33%, Rsig = 3.88%), and 10927 (90.48%) were greater than 2σ(F2). The final unit cell constant for a=8.6815(6)Å, b=12.9371(9)Å, c=32.676(2)Å, α=83.787(3)°, β=87.487(3)°, γ=89.930(3)°, and volume=3644.9(4)ų is based on the precision of the XYZ centers of 9845 reflections greater than 20σ(I) at 6.873°<2θ<130.4°. Absorption effect data were corrected using the Multi-Scan method (SADABS). The minimum-to-maximum ratio of apparent transmittance was 0.853. The calculated minimum and maximum transmittance coefficients (based on crystal size) were 0.9280 and 0.9550. The structure was elucidated and refined using the formula unit C40H57NO5, the Bruker SHELXTL software package, and the space group P-1 with Z=4. The final anisotropic complete matrix least squares refinement of F2 using 838 variables converged to R1=11.45% for observed data and wR2=26.68% for all data. The goodness of fit was 1.106. The maximum peak in the final difference of electron density synthesis at an RMS deviation of 0.073 e- / Å3 was 0.692 e- / Å3, and the maximum hole was -0.510 e- / Å3. Based on the final model, the calculated density was 1.151 g / cm3. Table 2 shows the atomic coordinates and equivalent isotropic atomic displacement parameters (Å) determined from the crystal structure of 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane. 2Table 3 provides the measured bond lengths (Å) determined from the crystal structure of 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane. Table 4 provides the measured bond angles (°) determined from the crystal structure of 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane. Table 5 provides the measured torsion angles (°) determined from the crystal structure of 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane. Table 6 provides the anisotropic atomic displacement parameters (Å) determined from the crystal structure of 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane. 2 Table 7 provides the hydrogen atom coordinates and isotropic atomic displacement parameters (Å) determined from the crystal structure of 3-palmitoyl-amide-2-hydroxy-1-dimethoxytriphenylmethyl ether-propane. 2 ) provides.

[0157] Figure 4A shows the Oak Ridge Thermal Ellipsoid Plot (ORTEP) diagrams of two different conformations of 3-palmitoyl-amido-2-hydroxy-1-dimethoxytrityl ether-propane determined by X-ray crystallographic analysis. Conformer A exhibits a linear conformation of 3-palmitoyl-amido-2-hydroxy-1-dimethoxytrityl ether-propane. Conformer B exhibits a bent conformation of 3-palmitoyl-amido-2-hydroxy-1-dimethoxytrityl ether-propane. Figure 4B shows the unit cell of the crystal of 3-palmitoyl-amido-2-hydroxy-1-dimethoxytrityl ether-propane, with each unit cell containing 3-palmitoyl-amido-2-hydroxy-1-dimethoxytrityl ether-propane of four molecules (two molecules of conformer A and two molecules of conformer B). Figure 4C shows a diagram of the crystal packing of 3-palmitoyl-amido-2-hydroxy-1-dimethoxytrityl ether-propane along the first axis, and Figure 4D shows the crystal packing of 3-palmitoyl-amido-2-hydroxy-1-dimethoxytrityl ether-propane along the second axis. Figure 4E shows the intermolecular hydrogen bonds between conformer A and conformer B along the second crystal structure analysis axis.

Table 2-1

Table 2-2

Table 2-3

Table 3-1

Table 3-2

Table 3-3

change

change

change

change

change

change

Claims

1. Compounds of formula II: 【Chemistry 15】 A crystal of (wherein DMTr is dimethoxytriphenylmethyl), wherein each unit cell of the crystal contains four molecules of the compound of formula II.

2. The crystal according to claim 1, wherein the crystal of formula II is monoclinic.

3. The crystal according to any one of claims 1 to 2, wherein each unit cell in the crystal contains two different conformations of the compound of formula II.

4. The crystal according to claim 3, wherein each unit cell contains the extended conformation and the bent conformation of the compound of formula II.

5. The crystal according to any one of claims 3 to 4, wherein each conformation of the compound of formula II is present in a 1:1 ratio.

6. The crystal according to any one of claims 1 to 5, wherein the unit cell has dimensions of 8.44 Å × 26.56 Å × 10.06 Å.

7. The aforementioned unit cell is 2254.8 Å. ３ The crystal according to claim 6, having the volume of [a certain value].

8. 1.2 g / cm ３ ~1.3 g / cm ３ The crystal according to claim 7, having the density of [value].

9. The crystal according to any one of claims 1 to 8, wherein the compound of formula II has a polymorphic purity of 95% or more.

10. A method for producing one or more single crystals of a compound of formula II, Contacting a composition containing one or more solvents with the compound of formula II, 【Chemistry 16】 A method comprising forming one or more single crystals of the compound of formula II, wherein one or more of the formed single crystals are in a monoclinic form, each unit cell of the crystal contains four molecules of the compound of formula II, and the one or more solvents contain dichloromethane and pentane.

11. The method according to claim 10, wherein the composition is brought into contact with the compound of formula II at a temperature of 10°C to 75°C.

12. The method according to claim 11, wherein the method comprises: heating the composition sufficiently to dissolve the compound of formula II; and cooling the heated composition after the compound of formula II has been dissolved.

13. The method according to any one of claims 10 to 12, wherein each single crystal contains two different conformations of the compound of formula II.

14. The method according to claim 13, wherein each unit cell of the single crystal includes the extended conformation and the bent conformation of the compound of formula II.

15. The method according to claim 13 or 14, wherein each conformation of the compound of formula II is present in a 1:1 ratio within each unit cell.

16. The method according to any one of claims 10 to 15, wherein the unit cell of each single crystal contains four molecules of the compound of formula II.

17. The method according to claim 16, wherein the unit cell has dimensions of 8.44 Å × 26.56 Å × 10.06 Å.

18. The aforementioned unit cell is 2254.8 Å. ３ The method according to claim 17, having the volume of

19. Each formed single crystal was 1.2 g / cm³ ３ ~1.3 g / cm ３ The method according to any one of claims 10 to 18, having the density of

20. The method according to any one of claims 10 to 19, wherein each formed single crystal has a polymorphic purity of 95% or more of the compound of formula II.

Images